

ORENCIA (ABATACEPT)

Infusion Orders

INFUS	ION CARE		PHONE	515.225.2930 FAX 515.559.2495
Patient Info	ormation	Fax completed for	rm, insurance information a	nd clinical documentation to 515.559.2495.
Patient Name:			DOB:	Phone:
Patient Status:		Continuing Therapy	Next Treatment Date:	
Medical Info	ormation			
Diagnosis:	Rheumatoid arthritis	Juvenile rheumatoid arthritis	Psoriatic athritis	
	GVHD prophylaxis	Other:		
100 10 0 1	CVIID PROPRIJIANS			
_	Ibs. (required)	Allergies:		
Therapy Ord	der			
Orencia Do	se: m	g IV Other dose:	:	**Max dose: 1000 mg**
				-
Frequency:	weeks 0, 2 and 4, then every 4 wee	eks there after x1 year or Ev	very 4 weeks x1 year	
	Other:			
				-
Premedication	orders: Tylenol 1000 mg	500 mg PO, please choose 1 a	antihistamine:	
	Cetirizine 10 mg PO	Diphenhydramine 25 mg F	PO Loratadine 10 mg PO	
Additional pre	medication orders: Solu-Med	rolmg l	VP	
	Solu-Cort	ef mg l	VP	
	Other:			
Lab Orders:			Frequency: Monthly	Other:
	Yearly QFT TB screening (optiona			
		•		
Required labs to	o be drawn by: Hy-Vee Health	Referring Provider		
Other:				
Anaphylactic re	eaction orders:			
	based on patient weight)			
	bs): EpiPen 0.3 mg or compounded	syringe IM or Sub-Q; may repeat	in 5-10 minutes x1	
• 15-30kg (33-	-66lbs): EpiPen Jr. 0.15 mg or compo	unded syringe IM or Sub-Q; may	repeat in 5-10 minutes x1	
 Diphenhydrar 	mine: Administer 25-50 mg orally OF	IV (adult)		
Refer to physic	cian order or institutional protocol fo	or pediatric dosing		
Flush orders: N	S 1-20 mL pre/post infusion PRN and	Heparin 10U/mL or 100U/mL per	r protocol as indicated PRN	
Physician Ir	nformation			
	form and utilizing our services, you ent in dealing with medical and pre			our prior authorization and specialty pharmacy
Provider Name		Signature:		Date:
Provider NPI:	Phor	ne: F	Fax:	Contact Person:
Opt out of H	y-Vee Health selecting site of care	(if checked, please list site of ca	re):	
Service Are	as			
Des Moines	s, IA West Des Moines, IA	Chicago, IL Omaha, NE	Buffalo, NY Dallas, T	X Phoenix, AZ Other



COMPREHENSIVE SUPPORT FOR ORENCIA (ABATACEPT) THERAPY

Patient Information				
Patient Name: DOB:				
Required Documentation for Referral Processing & Insurance Approval				
Include <u>signed</u> and <u>completed</u> order (MD/prescriber to complete page 1)				
Include patient demographic information and insurance information				
Include patient's medication list				
Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits or contraindications to conventional therapy. Has the patient had a documented contraindication/intolerance or failed trial of a DMARD, NSAID or conventional therapy (i.e., MTX, leflunomide)? Yes No If yes, which drug(s)?				
Does the patient have a contraindication/intolerance or failed trial to at least one biologic (i.e., Humira, Enbrel, Simponi, Cimzia)? Yes No If yes, which drug(s)?				
GVHD – Will Orencia be used in combination with a calcineurin inhibitor (i.e., cyclosporine, tacrolimus) and methotrexate? Yes No				
Include labs and/or test results to support diagnosis i.e., RF, anti-CCP, ESR, C-reactive protein				
If applicable – Last known biological therapy: and last date received:				
If patient is switching to biologic therapies, please perform a washout period of weeks prior to starting Orencia. Other medical necessity:				
Required Prescreening				
TB screening test completed within 12 months – attach results				
Positive Negative				
Hepatitis B screening test completed. This includes Hepatitis B antigen and Hepatitis B core antibody total (not IgM) – attach results Positive Negative				

Hy-Vee Health will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

*If TB or Hepatitis B results are positive, please provide documentation of treatment or medical clearance, and a negative CXR (TB+).

HY-VEEHEALTHINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee and contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.